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Abstract
Introduction: Clinical practice guidelines recommend comprehensive treatment for tobacco 
dependence including pharmacotherapies and behavioral interventions. Group counseling may 
deliver unique treatment aspects not available with other modalities. This manuscript provides a 
narrative review of group treatment outcomes from real-world practice settings and complements 
recent meta-analyses of randomized controlled trials (RCTs). Our primary goals were to determine 
whether group treatments delivered in these settings have yielded similar quit rates compared to 
individual treatment and to provide recommendations for best practices and policy.
Methods: Group treatment was defined as occurring in a clinical or workplace setting (ie, not pro-
vided as part of a research study), led by a professionally trained clinician, and offered weekly over 
several weeks. English language PubMed articles from January 2000 to July 2017 were searched 
to identify studies that included outcomes from both group and individual treatment offered in 
real-world settings. Additional data sources meeting our criteria were also included. Reports not 
using pharmacotherapy and research studies (eg, RCTs) were excluded. The primary outcome was 
short-term, carbon monoxide (CO)-validated point prevalence abstinence (4-week postquit date). 
Results: The review included data from 11 observational studies. In all cases, group treatment(s) 
had higher 4-week CO-validated quit rates (range: 35.5%–67.3%) than individual treatment(s) 
(range: 18.6%–53.3%).
Conclusions: Best practice group treatments for tobacco dependence are generalizable from re-
search to clinical settings and likely to be at least as effective as intensive individual treatment. 
The added advantages of efficiency and cost-effectiveness can be significant. Group treatment is 
feasible in various settings with good results.
Implications: A major barrier to achieving high rates of tobacco abstinence is under-utilization of 
evidence-based treatment interventions. This review demonstrates the effectiveness and utility of 
group treatment for tobacco dependence. Based on the available data described in this narrative 
review in conjunction with existing RCT data, group treatment for tobacco dependence should be 
established and available in all behavioral health and medical settings. Group tobacco treatment 
is now one of the mandated reimbursable tobacco treatment formats within the US health care 
system, creating enormous opportunities for widespread clinical reach. Finally, comprehensive 
worksite group programs can further extend impact.
Introduction
Tobacco use remains the leading cause of preventable death and dis-
ease in the United States.1 As of 2010, an estimated 8.7% of US 
annual health care spending, or as much as $170 billion per year, 
was attributable to smoking.2 Most people who use tobacco want 
to quit and engage in multiple quit attempts.3–6 Unfortunately, most 
quit attempts end in relapse.7 Clinicians routinely attempt to assist 
patients with overcoming cessation fatigue or tiredness in trying to 
quit tobacco.8 Low success in quitting and high relapse rates may 
partly be because only 31% of smokers making quit attempts use 
counseling and/or medication when trying to quit, which remains 
unchanged from 2005 to 2015.3 In fact, only 2.8% of patients mak-
ing a quit attempt reported using one-on-one counseling and only 
2.4% used a stop smoking clinic, class, or support group.3 Despite 
clear evidence-based research recommendations regarding the effect-
iveness of these tobacco treatments, there is a continuing need to 
evaluate and refine these recommendations as research is translated 
into practice. The latest US Public Health Service (PHS) Clinical 
Practice Guideline for Treating Tobacco Use and Dependence 
emphasizes optimal combinations of specialized behavioral and 
pharmacologic approaches.7 Medications primarily target cravings 
and components of addiction (eg, withdrawal symptoms), whereas 
behavioral approaches may modify psychosocial aspects of tobacco 
dependence, for example, helping patients establish new habits for 
managing tempting situations. Recommended formats for behav-
ioral approaches include individual and group face-to-face coun-
seling and telephone (eg, quitline) counseling.7
Theoretically, group-oriented tobacco treatment could foster sig-
nificant behavior change through therapeutic factors such as instill-
ing hope, universality, altruism, group cohesion, imitative behavior, 
and models of successfully coping with life without tobacco.9 Hajek 
et  al.10 and Hajek11 presented data that group tobacco treatment 
aiming to maximize group processes such as patient interaction and 
intergroup discussion among participants impacted outcomes more 
strongly than a traditional didactic or “class” style of group tobacco 
treatment. Group-oriented treatment led to significantly higher 
short- and long-term quit rates, as well as better attendance.10
A long history exists of efforts to promote group tobacco treat-
ment in the United States. Some patients reported using Smokenders 
group meetings in the 1970s, 1980s, and 1990s. Kanzler et  al.12 
reported that a 9-week Smokenders group program (n = 553) resulted 
in a self-reported, intent-to-treat 7-day point prevalence (PP) quit 
rate of 70% at the end of the program. Bakkevig et al.13 provided 
data from a randomized comparative trial of patients who received 
treatment from their general practitioner or attended an 8-week 
Smokenders group. At 2 months postquit date, 54% of Smokenders 
patients were smoke-free compared to 13% who saw their physician, 
based on self-report. During this same time period, the American 
Cancer Society and American Lung Association began promoting 
“Fresh Start” and “Freedom From Smoking” group classes, respect-
ively. An earlier version of these programs,14 which did not include 
medications, reported 3-month PP quit rates at 24%–29%; however, 
these programs have not been recently evaluated.
Three relatively recent reviews of group treatment outcomes 
from randomized controlled trials (RCTs) have been published. 
First, the US Preventive Services Task Force recently gave group 
treatment a grade A  recommendation, the strongest recommenda-
tion, primarily based on an earlier (2000) meta-analysis of 52 treat-
ment arms reported in the PHS Guideline.7,15 In comparison to no 
treatment, group treatments produced an odds ratio (OR) of 1.3 
(95% confidence interval [CI] = 1.1% to 1.6%), with an estimated 
long-term quit rate of 13.9%. Individual treatments (67 arms) pro-
duced an OR of 1.7 (95% CI = 1.4% to 2.0%) with an estimated 
16.8% long-term quit rate. Second, Mottillo et  al.16 conducted a 
meta-analysis of individual, group, and telephone counseling out-
comes from 50 RCTs (N  =  26 927)  conducted in Europe, North 
America, and Australia. All three formats were found to significantly 
increase smoking abstinence compared to controls, with ORs of 
1.49 (95% CI = 1.08% to 2.07%) for individual counseling, 1.76 
(95% CI = 1.11% to 2.93%) for group counseling, and 1.58 (95% 
CI  =  1.15% to 2.29%) for telephone counseling. Finally, a 2017 
Cochrane review concluded that group treatment has better out-
comes than no intervention, self-help programs, or receiving brief 
support from a health care provider.17 Also, this review reported that 
no differences in quit rates were found in six RCTs comparing group 
counseling and individual counseling approaches.17
In the United States, the Affordable Care Act now mandates group 
tobacco treatment as a covered preventive benefit by Medicaid and 
most private health insurance plans.18 Given that there has been no 
increase in the uptake of professionally assisted tobacco treatment 
utilization in the last decade,3 and given that there have been no 
recent comprehensive narrative reviews of group tobacco treatment 
outcomes from real-world clinical practice settings (ie, the treatment 
that patients received was not part of a clinical trial), this manuscript 
complements the reviews of RCTs described earlier and provides a 
new narrative review of recent group treatment outcomes in real-
world clinical settings for practitioners, public health professionals, 
and researchers. In this narrative review, we provide a qualitative 
and quantitative assessment of findings across heterogeneous obser-
vational studies, including different clinical settings, clinician types, 
populations, and outcome measures. We conducted a narrative re-
view19,20 because this approach can help clinicians and researchers in 
identifying and integrating clinical and setting treatment themes, to 
close practice gaps observed across studies, and to generate hypoth-
eses for future research. We have restricted our policy recommenda-
tions to the United States, given our familiarity with the US health 
care system (six authors are practicing clinicians in the United States) 
and the significant differences between the US health care system 
versus other countries.
We had three primary aims for our review. Our first aim was to 
compare group treatment quit rates to similarly intensive individ-
ual treatment quit rates in real-world clinical settings in which both 
types of treatment were available. A  second aim was to compare 
group and individual treatment results in real-world clinical prac-
tice settings to outcomes from traditional research studies (ie, RCTs), 
given often significant differences between treatment delivered in the 
context of research studies (ie, exclusion of patients with medical 
and behavior health comorbidities,21 treatment delivered by spe-
cially trained research staff, participants complete extensive research 
assessments and are paid for participation/travel, participants ran-
domly assigned to treatment condition) and treatment delivered in 
real-world clinical practice settings (ie, inclusion of all tobacco users 
who want to quit, patient may choose group vs. individual). Finally, 
we sought to elucidate contemporary best clinical practices for com-
prehensive group tobacco treatment.
Methods
Group treatment was defined as occurring in a real-world clinical 
practice or workplace setting (ie, not in the context of a research 
study), led by a professionally trained clinician, and offered weekly 
for at least several weeks to groups of more than two participants. 
Given that there is strong evidence that combining counseling 
with medication results in better outcomes than either counseling 
or medication alone,7 and that many real-world practice settings 
routinely use multiple, over-the-counter (OTC)  quitting medica-
tions,22,23 we restricted our review to treatment provided after the 
year 2000, when the nicotine lozenge, a popular medication, was 
more widely available OTC (eg, nicotine lozenge was approved to 
be sold OTC in mid-1999 in the United Kingdom and in late 2002 
in United States).
Search Strategy
English language PubMed articles from January 2000 to July 2017 
were searched using the following search string: ((smoking[Title] 
OR tobacco[Title]) AND group[Title/Abstract]) AND (session[Title/
Abstract] OR class[Title/Abstract] OR therapy[Title/Abstract] 
OR psychotherapy[Title/Abstract] OR counseling[Title/Abstract] 
OR treatment[Title/Abstract]) AND (“2000/01/01”[PDAT]: 
“3000/12/31”[PDAT]) AND “humans”[MeSH Terms] AND 
English[lang] AND “adult”[MeSH Terms] NOT Randomized 
Controlled Trial[ptyp]. Two authors independently reviewed 
the abstracts of all articles identified by this search. Articles were 
selected based on predetermined inclusion and exclusion criteria 
(Table  1). A  third author was available to resolve any discrepan-
cies. Reference lists of included articles were also searched for add-
itional data sources that met our criteria but were not identified by 
the PubMed search. Finally, other real-world data sources that were 
already known to the authors were included if they met our criteria 
and were deemed to potentially contribute to the understanding of 
group treatment best practices. If data were presented only in ORs, 
authors were contacted to provide sample sizes and short-term quit 
rates whenever possible.
Review Outcomes
Our primary outcome of interest was short-term, carbon monox-
ide (CO)-validated PP quit rate at 4 weeks after the target quit 
date. Also, when possible, similar to the work of Roberts et al.,24 
we reported on PP quit rates at the last follow-up if it was after 
4 weeks.
Results
The PubMed search initially returned 718 articles. Many articles at 
this stage were eliminated because they were not relevant (ie, focus 
group studies, hypnosis, acupuncture, e-cigarettes, financial incen-
tives, texting, quitline, etc.). After abstract review, 31 full articles 
were selected for further review and 6 articles were included in our 
review. Many of the articles excluded at this second stage described 
brief single visit treatment; did not provide data comparing multi-
session, one-on-one formats versus group treatment; did not include 
quitting medications; and/or did not report amounts of medications 
used or prescribed. Three additional data sources from real-world 
practice settings were identified by reviewing the references from 
identified articles. Finally, data from two additional real-world data 
Table 1. Study Inclusion and Exclusion Criteria
Inclusion criteria Exclusion criteria
1. Observational studies or treatment delivered in a real world clinical
practice setting (ie, not in the context of a research study) and included
patients in both group treatment and individual treatment
1. Randomized controlled trial (RCT) or treatment delivered in the
context of a prospective research study
2. Patients were motivated to quit and practice settings accepted all
patients seeking treatment
2. Some patients were excluded because of comorbidities (eg, medical, 
psychiatric, and/or active alcohol or illicit drug use)
3. Counseling was moderate to high intensity (ie, at least weekly visits) 3. Treatment was brief or provided in a single visit
4. US FDA-approved medications were used by at least 70% of patients 4. US FDA-approved medications were not used or reported
5. Outcomes were reported at 4-week postquit date (CO validated, if
possible)
6. Quit rates were reported using 7- or 14-day point prevalence abstinence
7. Intent-to-treat analyses were conducted (patients lost to follow-up were
included in the denominator when calculating quit rates)
CO = carbon monoxide; FDA = Food and Drug Administration.
sources already known to several of the authors were included for 
11 observational studies meeting criteria for this review (Table 2).
Sample sizes listed in Table 2 may not match the total Ns reported 
in the text because some samples included patients who did not 
receive group or individual treatment. Although we did not re-
strict our literature search to any specific location or country, all 
studies that met our criteria were from one of two countries: the 
United Kingdom (N = 9) or the United States (N = 2). Therefore, 
we decided to group them by country (United Kingdom vs. United 
States) given the significant differences in the health care systems 
between those two countries. Outcomes from both countries were 
based on quit rates at 4 weeks after the target quit date. However, 
UK outcomes followed the Russell Standard25 of 14-day PP (“Have 
you used any tobacco in the last 14  days, even a single puff?”), 
whereas US studies reported 7-day PP (“Have you used any tobacco 
in the last 7 days?”).
UK Studies
All UK sources reported on individuals who used the Stop Smoking 
Services (SSSs), offered through the single payer National Health 
Service, with locations throughout the United Kingdom. The 
National Health Service SSS, established in 1999, provides both be-
havioral support (individual and/or group) by trained smoking ces-
sation advisors and medication.28 Advisors can be specialists whose 
job consists only of providing smoking cessation services, or other 
health care providers (eg, pharmacists, physicians) who provide 
smoking cessation services as part of their job. Specific programs and 
medications available have changed over time and vary by location.
Judge et al.29 reported on outcomes of nearly 7000 patients who 
used SSS between 2001 and 2003 in: (1) Nottingham, an ethnically 
diverse city in the East Midland region with many areas of low soci-
oeconomic status (SES) and (2) North Cumbria, a rural area in the 
northwest. Patients typically received 5 weeks of counseling, starting 










(% non-White) Clinician type Medications
Judge (2005) 321 57 6 523 53.3 England (3.2) Smoking cessation advisor NRT; bup
McEwin (2006) 822 42 679 32 England (12) Clinic cessation specialists (G); 
community pharmacists or PC  
nurses (I)
NRT; bup
Bauld (2006) 448 44.4 11 126b 20.2 Scotland (0) Smoking cessation advisor (G);  
community pharmacists (I)
NRT; bup (G);  
NRT (I)
Bauld (2009) 411 35.5 1 374 18.6 Scotland (NR) Community cessation  
specialists (G); network 
pharmacist or pharmacy  
assistant (I)
NRT; bup; var (G); 
NRT (I)
Brose (2011) 8 966c,d 49.9 114 672c,e 35.4 England (14.8) Trained advisors in PC;  
specialist clinics; pharmacy;  
other settings
NRT; var; bup
Mardle (2012) 318f 67.3 870 50.7 England (NR) PCT-led specialist teams; 
community-based health  
care providers
NRT; var; bup




123 321e 33.9 England (11.8) Specialist; GP; nurse; health care 
assistant; pharmacy staff
NRT; bup; var








England (10.7) Specialist; GP; nurse;  





145 61.4 338e 50.9 England (26) Specialist NRT; bup; var





212j,k 59.0 1 427j,k 46.0 United States 
(33.8)
Specialist NRT; bup
bup = bupropion; c = closed; G = group; GP = general practitioner; I = individual, NR = not reported; NRT = nicotine replacement therapy; o = open; PC = primary 
care; PCT = Primary Care Trust; var = varenicline.
aQuit rates are 14-day point prevalence abstinence for England and Scotland studies and 7-day point prevalence abstinence for US studies.
bOne-to-one individual treatment with pharmacist.
cRaw data provided by L. Brose (personal communication, January 4, 2017).
dIncludes both open and closed group.
eIncludes individual drop-in.
fIncludes open, closed, and workplace groups.
gIncludes some overlapping patient data from Hiscock et al.26
hIncludes those who attended at least one group session.
iIncludes those who attended at least one individual session.
jIn addition to the sample shown for group only and individual only, another 888 patients received both group and individual (quit rate of 62.1%) treatments.
kIncludes some overlapping patient data from Foulds et al.27
1 week before quitting and continuing 4 weeks after a target quit 
date. Most patients (about 70%) received nicotine replacement ther-
apy (NRT), with 18%–20% receiving bupropion and 2%–3% com-
bined NRT and bupropion. The CO-validated 4-week quit rate was 
53.3% in individual versus 57.0% in group treatment. In a multi-
variate analysis, group treatment demonstrated a significantly higher 
CO-validated quit rate, OR = 1.38 (95% CI = 1.09% to 1.76%) 
compared to individual treatment. Primary limitations of this study 
are the small proportion of patients who received group treatment 
(n = 321) versus individual treatment (n = 6523), and no informa-
tion reported on the equivalence of dosing (ie, minutes of counseling) 
between individual and group treatments. Rural and semirural areas 
had lower group treatment turnout.
McEwen et al.30 compared group treatment provided by special-
ist counselors receiving ongoing supervision (n = 822) versus individ-
ual treatment offered by Community Advisors, mostly pharmacists 
and primary care nurses, (n = 679) in the outer boroughs of London 
between 2001 and 2003. Counseling content was “withdrawal-
oriented” and nearly identical in both treatment formats. Groups 
consisted of 30–60 patients and met weekly for 6 weeks, with each 
meeting up to 2 hours. Individual treatment included six weekly ses-
sions of about 30 minutes per visit. Most patients (75%) used NRT, 
with 22% using bupropion. CO-validated 4-week quit rates were 
higher in group treatment (42%) than individual treatment (32%). 
The difference in the odds of quitting remained significant even after 
controlling for possible confounding factors, such as level of depend-
ence and patient demographics such as race and ethnicity and SES 
(p < .001).
Bauld et al.31 reported on group treatment (n = 448) and indi-
vidual treatment (n = 11 126) outcomes in Scotland from 2004 to 
2005, with a high number of low-income tobacco users. Offered in 
multiple venues (eg, health center, other community venues), group 
treatment included seven weekly visits, with the quit date at the third 
week. Both medical and nonmedical professionals who had received 
specialist training delivered the group treatment. Almost all patients 
in group treatment used NRT; very few (<20) used bupropion. 
Individually treated patients received services in 167 participating 
pharmacies. All patients in individual treatment received NRT (16-
hour patch). Pharmacists or pharmacy assistants provided coun-
seling for at least five weekly sessions with the quit date at week 
1. Patients remaining in the program at week 5 could continue for
up to seven additional weeks. Often there was no privacy, with coun-
seling occurring at the counter where clients received patches. Many
patients received a longer first session with the pharmacist, but sub-
sequent visits were often very short (eg, about 5 minutes). Overall,
this pharmacy treatment format may have been more of a brief-to-
moderate intensity intervention, compared to the longer duration of
group treatment counseling. The CO-validated quit rate at 4-week
follow-up was 44.4% for group treatment versus 20.2% for phar-
macy treatment. These two treatment models were set up differently
and were not meant to be compared directly. For example, phar-
macy patients initially set a quit date and received NRT at their first
visit, but many did not return for a second visit. Thus, less moti-
vated patients may have been included in the intent-to-treat quit
rates, in comparison to patients who received group treatment. The
pharmacy later introduced an additional introductory visit (“week
zero”), with NRT provided at the second visit. Additionally, another
study limitation was that patients needed to fail the patch before
trying other medications.
Bauld et  al.32 conducted another analysis of group (n  =  411) 
versus pharmacy-provided individual (n  =  1374) treatment in 
Glasgow, Scotland, in 2007; both groups included many with low 
SES. Group treatment participants met in 1-hour weekly sessions 
for 7 weeks. Individual treatment patients received an initial assess-
ment (>15 minutes) followed by 12 weekly visits (5–15 minutes). 
Patients in the group treatment received NRT (84%), bupropion 
(3%), or varenicline (13%), whereas all patients in the individual 
treatment received access to 16-hour nicotine patch (100%). Again, 
the CO-validated quit rate at 4 weeks was higher for the group 
treatment (35.5%) versus the individual treatment (18.8%). This 
difference was significant after controlling for a range of participant 
characteristics (ie, level of addiction and SES) and pharmacothera-
pies used (OR = 1.98, 95% CI = 1.50% to 2.62%). As with the prior 
report, individual treatment may have been less intensive than group 
treatment.
Brose et al.33 provided retrospective data from 126 890 treatment 
episodes in 24 SSS locations in the United Kingdom between 2009 
and 2010. Treatment formats included intensive individual and group 
treatment in primary care, specialist clinics, and pharmacy settings. 
About 88% of patients used medications (varenicline, bupropion, or 
NRT), with specialist clinics more likely to prescribe combination 
NRT or varenicline for highly dependent patients. Controlling for a 
number of client characteristics (ie, race and ethnicity, SES, addiction 
severity) and intervention variables, both closed and open (ie, roll-
ing admission) group treatments had higher 4-week CO-validated 
quit rates compared to individual treatment (OR  =  1.43, 95% 
CI = 1.16% to 1.76% for closed; OR = 1.46, 95% CI = 1.19% to 
1.78% for open). Raw data provided (L. Brose, personal communi-
cation, January 4, 2017) showed that closed groups had a 49% quit 
rate and open groups had a quit rate of 50.6%, compared to individ-
ual treatment (including drop-ins) quit rate of 35.4%
Mardle et al.34 conducted an analysis of SSS provided through 
three Primary Care Trusts (PCTs) in England (Bournemouth and 
Poole, South East Essex, and Warwickshire) in 2008. Group treat-
ment was provided by a PCT specialist team in one setting. Another 
PCT provided treatment by PCT-led specialist teams, including a mix 
of a PCT-led specialist team, primary care practitioners, pharmacists, 
dentists, and opticians. One of the PCTs offering groups had three 
options (closed, rolling, and workplace groups), whereas the other 
only offered closed groups. In all three PCTs, the majority of partici-
pants used NRT (55.8%–65%), with 24.5%–34.3% using vareni-
cline and 3%–4% using bupropion. Once again, group treatment 
resulted in higher CO-validated 4-week quit rates (54.9%–76.2%) 
versus individual treatment (42.6%–51.2%), but the data did not 
control for client factors such as level of motivation. The authors 
suggested that service structure, treatment format, health care pro-
fessional involved, and pharmacotherapy all played a role in the 
variable quit rates. Although closed groups had the highest quit 
rates, it was noted that patient choice and tailoring of patient needs 
are key treatment factors. It was also noted that group treatment was 
not feasible in many rural areas.
Hiscock et al.,26 in a retrospective study, provided CO-validated 
4-week quit rate data for 132 586 quit attempts by patients aged
19–59 in England who accessed National Health Service SSS between 
2010 and 2011. Most patients were treated by specialists, general
practitioners, nurses, health care assistants, or pharmacists. More
than half were seen by specialist clinicians. Nearly 79% reported
using medications (single NRT, combination NRT, bupropion,
varenicline, or a mixture). The quit rate for individual treatment was 
33.9% versus 50.8% for open groups and 49.1% for closed groups. 
In a multivariate analysis, controlling for some patient characteris-
tics (race and ethnicity and SES), open group treatment was more 
successful than individual counseling (OR = 1.26, 95% CI = 1.12% 
to 1.41%) for most clients (not including prisoners and the long-
term unemployed).
Dobbie et al.28 conducted an analysis of retrospective data from 
49/150 SSS centers (N  =  202 804 cases) from July 2010 to June 
2011in England. The dataset overlapped with data presented by 
Hiscock et al.26 Whereas Hiscock et al.26 restricted their analysis to 
patients aged 19–59, Dobbie et  al.28 included patients of all ages. 
Almost all patients received medication, with a significant propor-
tion receiving varenicline and the rest NRT (single or combination), 
and patients who saw specialist practitioners had higher quit rates 
than patients who saw other types of practitioners. In the analysis, 
most patients (n  =  140 119, 79%) received individual treatment, 
whereas only 2.7% (n  =  4780) received open group treatment, 
and 1.4% (n  =  2512) received closed group treatment. However, 
the CO-validated 4-week quit rate was 33.8% for individual treat-
ment, 52.1% for open groups, and 50.1% for closed groups. Open 
groups were significantly more effective than individual treatment 
(OR = 1.28, 95% CI = 1.15% to 1.41%).
Finally, McAlpine et al.35 conducted an analysis of 516 patients 
seen at a single specialist clinic (Whitechapel) in London from 2013 
to 2014, representing a higher proportion of males or ethnic minori-
ties than the national average. Treatment typically included seven 
weekly sessions in individual or group (closed or open) format. 
Nearly all patients received pharmacotherapy, with 49% receiving 
NRT and 47% receiving varenicline. The 4-week, CO-validated 
quit rate was higher for patients who received closed group tobacco 
treatment (61.4%), compared to individual treatment (50.9%).
US Studies
Only two US studies meeting criteria were identified in the United 
States. Due to the complex health care system and billing difficulties 
with face-to-face counseling,36,37 group treatment is not widely avail-
able in the United States. Many tobacco users in the United States 
may only receive brief physician advice and/or some quitline support.
Foulds et al.27 conducted a retrospective cohort study involving 
1021 patients who received treatment at the Tobacco Dependence 
Program at the University of Medicine and Dentistry of New 
Jersey (UMDNJ) School of Public Health. This specialist clinic has 
provided free treatment since 2001. The percent of racial-ethnic 
minorities who received treatment was similar to the proportion of 
racial-ethnic minorities in the population of New Jersey in 2007.38 
Treatment included an initial 50–75 minutes assessment followed 
by individual or group counseling. Group treatment consisted of six 
weekly 90-minute group sessions with the target quit date at week 
2. Patients also received free and/or discounted OTC NRT and pre-
scription medications (bupropion, nicotine inhaler, and nicotine
nasal spray). Overall, 87% reported using medications. After con-
trolling for other significant patient predictors (SES and addiction se-
verity), patients who attended at least one group treatment meeting
(n = 448) had higher self-reported quit rates (7-day PP) at 4 weeks,
compared to those who attended only individual treatment visits
(n = 279), 57.6% versus 47.7%, p = .04. This difference remained
significant at 6-month postquit (41.3% vs. 28.7%, p = .02). A limi-
tation of the study is that only 39% of patients were seen in person
at 4-week follow-up and therefore able to provide a CO sample.
Therefore, some of the patients’ self-report was not biochemically
validated. However, 99.2% of the patients who self-reported abstin-
ence and had their CO measured had CO less than 10 ppm, validat-
ing their self-report.
An evaluation of a state-wide program funded by the New Jersey 
Department of Health and Senior Services describes outcomes from 
patients (N = 4975) enrolled in individual and group face-to-face treat-
ment at 15 hospital-based programs at New Jersey Quitcenters from 
2001 to 2006.39 The percent of racial-ethnic minorities who received 
treatment was similar to the proportion of racial-ethnic minorities 
in the population of New Jersey in 2007.38 Patient costs were free or 
minimal, including some free and discounted OTC NRT. The average 
patient was moderately dependent on tobacco and attended 5.4 treat-
ment visits, including the intake. The treatment visits were either indi-
vidual or group counseling, or a combination of individual and group 
treatment. Breath CO testing occurred at each visit. Most patients 
(79%) used at least one US Food and Drug Administration-approved 
medication. Group treatment visits were either in structured, closed 
6-week group programs or rolling, open group meetings, depending
on treatment setting. In addition, over 75% of participants rated pro-
gram satisfaction very high. The vast majority were treated at the
clinic-based programs, with a minority treated at worksite programs
and/or community settings in a closed group treatment format. The
overall intent-to-treat quit rate at 6 months postquit date was 24.4%, 
but the report did not distinguish between the types of counseling
received or short-term quit rates.
A subsequent analysis of the same New Jersey Quitcenter data con-
ducted by the New Jersey Department of Health (M. Santorelli, per-
sonal communication, 2015) determined that among those completing 
an intake, nearly 46% participated in at least one individual counseling 
session following the intake, and nearly 22% participated in at least 
one group counseling session. The average duration of individual coun-
seling sessions was 49 minutes and, among patients who participated, 
the average number of individual visits completed by the 4-week fol-
low-up was 2.1 (excluding intake meeting). The average duration for 
group counseling sessions was 80 minutes, and participants averaged 
4.1 visits, indicating that typically these patients received more overall 
treatment exposure time. Furthermore, the 4-week intent-to-treat quit 
rate (7-day PP) was 59% for patients who only received group treat-
ment versus 46% for those who only received individual counseling. 
Those who attended individual and group meetings combined reported 
a short-term quit rate of 62.1%. Six-month intent-to-treat quit rates 
were 45.7% for patients participating in group treatment, 37.8% for 
patients in individual counseling, and 49.6% for patients who received 
both individual and group treatments.
It should be noted that there was some overlap in Foulds et al.27 
data published in 2006 and this subsequent analysis of New Jersey 
data, because the clinic associated with the Foulds et  al.27 study 
was one of the 15 networks of Quitcenters, which all used simi-
lar databases to measure patient demographics and quit outcomes. 
These programmatic outcomes are compelling, but they are limited 
in that patient abstinence was not independently evaluated in all 
cases, because CO testing validated self-report only when avail-
able. Although there were limitations in the data, more than 99% of 
patients (630/634) who reported quitting had CO testing less than 
10 ppm, validating their self-report.
Discussion
Recent reviews of RCTs have revealed that group-based treat-
ment for tobacco dependence appears to be at least as efficacious 
as individual counseling treatment. Given that group treatment is 
now a mandated covered health insurance benefit under the US 
Affordable Care Act, and that real-world clinical practice settings 
may differ from research settings, we conducted a narrative review 
of group treatment outcomes in real-world practice settings, which 
were available from the United Kingdom and the United States In 
these settings, group treatments resulted in higher quit rates than 
individual treatments, suggesting that best practice group treatments 
are generalizable and can be transferred from research to clinical 
settings. Our results support the hypothesis that group treatment is 
at least equal to or possibly more effective than individual treatment.
Overall, the group quit rates observed in these real-world prac-
tice settings are consistent with and may be higher than the esti-
mated quit rates from RCTs reported in prior meta-analyses. High 
quit rates in these settings show the benefits of strong integration 
and dose of treatment (medications plus intensive counseling), often 
in a “one stop shop” where patients received medications and coun-
seling in the same physical location. Our review also indicates that 
both open and closed groups can produce similarly high quit rates. 
In particular, open or rolling admission groups may capitalize more 
on patient motivation, because these patients can immediately enter 
treatment.
A clear pattern in studies emerged that group treatment is more 
feasible in more populated areas. Many rural or semirural settings 
had a stronger preference for one-on-one treatment and signifi-
cantly lower attendance at group treatment programs. Also, more 
treatment contact visits were associated with higher short-term 
quit rates, likely at least partly due to increased medication com-
pliance. For example, Foulds et al.27 reported that patients attend-
ing at least six more visits had a 69.9% quit rate. Similarly, in a 
prospective study by Dobbie et al.,28 six patient visits lead to a quit 
rate of 65.3%. Novel engagement strategies for maximizing attend-
ance appear to involve combinations of key programmatic factors: 
free medication(s) scheduling more treatment visits40 around the quit 
date, and “re-recruiting” smokers with slips or relapses.  These types 
of interventions also led to high short- and long-term quit rates in 
the Lung Health Study.41–43 Additionally, moderate- and longer-term 
quit rates were achieved with similar comprehensive intensive group 
interventions by Hall et al.44,45
Limitations
Many potential complexities may exist in the interpretation of 
these clinical reports. First, clinicians leading groups (often tobacco 
treatment specialists) may have had more experience than clini-
cians providing individual counseling (eg, pharmacists), and these 
more experienced clinicians may be the causal agents accounting 
for higher quit rates in group treatment. More recently, Song et al.46 
reported higher longer-term quit rates from specialist services com-
pared to nonspecialist services, suggesting that more extensive train-
ing, supervision, and adherence to evidence-based practices lead to 
better outcomes. It is also possible that more experienced specialist 
clinicians are able to help patients correctly use medications or man-
age medication side effects so that medication adherence improves, 
as indicated by Dobbie et al.28
Another limitation, which applies to all outcomes from practice 
settings, is that patients were not randomly assigned to group versus 
individual treatment as in RCTs. In some reports, it was not clear 
how patients were allocated to group versus individual treatment and 
may have depended on availability, whereas in some cases patients 
self-select group or individual treatment modality. Individuals who 
choose group treatment may have different characteristics than 
those who choose individual treatment (eg, demographics, person-
ality, and motivation). These characteristics may be independently 
associated with likelihood of quitting, regardless of the type of coun-
seling received, and only some of the studies discussed here tried to 
control for baseline characteristics. It may be possible that in some 
studies, patients with more severe addictions, lower SES, and/or 
more severe psychiatric and/or substance use disorder comorbidi-
ties were steered by clinicians into individual treatment for clinical 
reasons more frequently, which could potentially bias the results in 
favor of group outcomes. On the other hand, five of the studies revi
ewed30,32,33,26,27 that did control for many of these patient character-
istics, particularly SES and severity of addiction, still found group 
treatment quit rates to exceed one-on-one formats. Additionally, the 
Brose et al.32 discussed that the most successful intervention (group 
treatment) tended to have more severely dependent tobacco users, 
suggesting that the clients with more complexities are not necessarily 
choosing individual treatment. Finally, although our review included 
hundreds of thousands of patients, there is a risk of potential bias 
in our review, because we limited our database search strategy to 
PubMed and studies published in English.
Research Recommendations
The results of our review suggest several directions for future research. 
First, research should focus on identifying active group treatment 
mechanisms, possibly through analysis of behavior change tech-
niques47–49 and optimal group characteristics. An example includes 
exploring the impact of clinician interventions of prompting group 
interaction between group members. Another key example may be 
coding how patients were instructed in the correct use of quitting 
medication and/or how the clinician prompted intergroup dialogue 
on correct medication use (eg, intergroup discussion between veteran 
and novice group members). This may be critical, because combin-
ation medication is now more common in practice settings,23 with 
seven US Food and Drug Administration-approved medications 
often used in different combinations (and different dosages) with 
patients with more comorbidities and higher levels of dependence. 
Another example includes examining the impact of ongoing inten-
sive clinical supervision provided to tobacco treatment specialists on 
ensuring higher quit rates for group treatment and accurately exam-
ining the impact of treatment fidelity as suggested by Song et al.46
Siu et al.,15 referring to earlier PHS Guidelines,7 suggested that 
cessation rates might plateau after 90 minutes of total counseling 
contact time. On the other hand, in reviewing newer data, Siu et al.15 
also noted that the largest effect was found in interventions that 
provided eight or more visits (although this was not significant). It 
was also noted that more or longer visits (ie, ≥20 minutes/visit for 
individual treatment) led to higher quit rates. This may appear to be 
confusing to clinicians, because optimal time amounts for group and 
individual counseling may differ, but appear to have been combined 
in earlier meta-analytic studies. Future research should determine the 
optimal clinical “dosage of counseling” (ie, the number and duration 
of visits) and the ideal group size range. For example, commenting 
on a trend for studies with longer or more visits to lead to higher 
quit rates, Stead and Lancaster50 noted a clear difference in ORs in 
earlier PHS Guidelines between 2 and 3 visits, compared with more 
than 8 visits (OR = 1.4, 95% CI = 1.1% to 1.7% vs. OR = 2.3, 95% 
CI = 2.1% to 3.0%). Again, these studies were earlier meta-analytic 
studies (2000) and did not break out format by individual or group, 
so optimal group dosing remains unclear in contemporary real-world 
practice settings. Future studies (ie, observational reports, RCTs, or 
prospective effectiveness studies) could assist in clearly indicating 
counseling time amounts delivered for individual and group coun-
seling, to assist in comparisons of counseling dosing across studies.
The newer data in our review seem consistent with recent recom-
mendations of Public Health England,51 indicating that of all treat-
ment formats, group treatment (6–12 visits) plus pharmacotherapy 
had the highest effectiveness and largest effect size. Our review syn-
thesis provides additional data supporting more intensive and com-
prehensive treatments (>4 sessions, >300 minutes total) per quit 
attempt, leading to high quit rates demonstrating high clinical sig-
nificance in a variety of typical clinical practice settings.
Emerging evidence is also now showing that 1:1 telemedicine (ie, 
audiovisual, Health Insurance Portability and Accountability Act 
compliant) tobacco cessation counseling is equally effective to quit-
line counseling, with higher participant satisfaction and medication 
compliance.52 Additionally, a recent telehealth videoconferencing 
group tobacco program has also shown feasibility with comparable 
quit rates to face-to-face group treatment in rural and urban areas 
of Canada.53 Thus, future research studies could examine group 
tobacco treatment mechanisms delivered via a telemedicine format 
more systematically, particularly in rural areas where face-to-face 
group treatment is difficult to establish. Finally, there is an urgent 
need for additional research on culturally sensitive group interven-
tions. Webb Hooper et al.54 have shown initial promising results with 
a culturally tailored intervention on early quit rates for lower income 
Black tobacco users.
US Health Care Systems Change and Policy 
Recommendations
Several additional rationales beyond quit rates support offering 
group treatment. First, patient and clinician satisfaction remains 
high in group tobacco treatment in many cross-cultural settings.28,39 
Therefore, patient experience or preference for treatment needs to 
remain a key factor in the referral process. We acknowledge that 
some individuals will always prefer individual, face-to-face, tele-
phonic treatments or other nongroup options. Electronic or fax-to-
quit referral could be implemented more widely (eg, from primary 
care physicians and other medical specialists) to outpatient tobacco 
treatment clinics incorporating group treatment formats. These 
referrals could also be initiated directly from inpatient tobacco treat-
ment programs, which are rapidly increasing in US hospitals,55 partly 
due to new Joint Commission standards.56
Second, group treatment is a standard of care for other substance 
use disorders (alcohol and illicit drugs).22,57 Many of these patients 
also use tobacco. Prior successful encounters in group treatment 
may increase these patients’ receptivity to a group tobacco treatment 
modality due to prior earlier experiences in developing mastery skills 
and social identity change experiences acquired in similar recovery 
intervention formats.58,59
Third, evidence-based worksite wellness tobacco treatment 
group programs have a strong potential to increase engagement 
in tobacco use treatment for those who are not reached in clinical 
settings.60 As indicated in Supplementary Appendix A, a sample 
closed 6-week group treatment protocol (adapted from an out-
patient tobacco treatment clinic), demonstrated high attendance 
and high quit rates.23,27,39,60 This type of program would be some-
what comparable with worksite weight management wellness pro-
grams. Supplementary Appendix B includes examples of billable, 
clinic-based group reimbursable current procedural terminology 
codes, which can make tobacco cessation services sustainable in 
health care settings. Group treatment can be administered by clini-
cians such as Certified Tobacco Treatment Specialists, who are likely 
to implement high-fidelity group treatment protocols. These clini-
cians are trained in the core competencies outlined by the Association 
for the Treatment of Tobacco Use and Dependence (www.attud.org) 
through programs accredited by the Council for Tobacco Treatment 
Training Programs (www.ctttp.org).
Finally, there is growing evidence that while group treatment is 
likely to be at least as effective as individual treatment, it is more 
cost-effective than individual treatment.61–63 Ensuring access to 
group treatment may therefore result in reducing the cost burden 
on health care systems, insurers, and other payers (eg, businesses 
who self-insure). Also, because tobacco treatment is ranked one of 
the most cost-effective treatments of all preventive interventions,64 
widespread tobacco group treatment implementation in health care 
settings would clearly reduce health care costs nationally, consist-
ent with the Triple Aim of population health,65 now incorporated 
within the Affordable Care Act.66 Because of the ratio of clinician-
to-patient time, group treatment is more efficient than individual 
treatment and, therefore, likely significantly more cost-effective. Due 
to the relationship between number of visits and outcomes, co-pays 
should not be added for each treatment visit. Creative reimburse-
ment methods could be used with Medicare policies to encourage 
group treatment participation. Providing sufficient coverage and 
reimbursement for group treatment would place Medicare on par 
with newer, updated15 evidence-based treatment formats now man-
dated within private insurance and Medicaid plans. This will remain 
vital to realizing the high cost-effective benefits with many Medicare 
tobacco users accessing the new lung cancer screening programs 
seeking effective tobacco treatment services.67,68
Conclusion
Based on the available data from RCTs, meta-analyses, and typical 
clinical practice experiences in this narrative review, group treat-
ment for tobacco dependence is at least as effective as—and possibly 
more effective than—individual counseling. The added advantages 
of efficiency and thus cost-effectiveness make this modality prefer-
able. These results also demonstrate that group treatment is clearly 
feasible in various settings with good results. Thus, group treatment 
could and should be established and available in all behavioral 
health and medical settings.
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